SWISF - New to The Street Announces Episode 551 Five Corporate Interviews Airing on the FOX Business Network Monday January 29 2024 at 10:30 PM PT | Benzinga
NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a national TV show, announces episode 551, airing on the FOX Business Network on Monday, January 29, 2024, at 10:30 PM PT.
New to The Street's 551st episode line-up features the following Five (5) Corporate interviews:
1). Biopharmaceutical -Acurx Pharmaceuticals, Inc.'s (NASDAQ:ACXP) () interview with David Luci, President/CEO.
2). Financial Marketplace Strategies – Blue Castle Ventures LTD's () interviews with David Rojas, CEO/Founder.
3). Decentralized Supercomputing – Dynex's (CRYPTO: DNX) () interview with Clifford Mapp, an Independent Technology Expert and Blockchain Pioneer.
4). Sustainable Solutions - The Sustainable Green Team, Ltd.'s (OTCQX:SGTM) () interview with Tony Raynor, CEO and Founder.
5). "Sekur Privacy & Sekur Security – Weekly Hack" segment with internet privacy expert Mr. Alain Ghiai, CEO, Sekur Private Data, Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA: GDT0) () (Sekur®).
Episode 551
New to The Street's TV Host Jane King from the Nasdaq MarketSite Studio talks with David Luci, the President/CEO of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) (). As a clinical-stage biopharmaceutical business, ACXP is developing a new class of antibiotics for life-threatening bacterial infections. David updates viewers on the Company's FDA Phase 2 clinical trial on the Ibezapolstat drug, a treatment for patients with Clostridioides difficile Infections (CDI). Based on positive data from Phase 2a and Phase 2b, management is now going forward with the FDA Phase 3. The Company compared its top-line data with the currently used standard-of-care drugs in the marketplace, and Ibezapolstat has impressive positive results. Phases 2a and 2b confirmed that the drug had success in 25 out of 26 patients, approximately 94% success with no reinfections. In treated patients, the microbiome bacteria found in the digestive tract shows the bacteria maintaining and restoring itself within those patients after a 10-day treatment. At a recent microbiome conference presentation in Texas, the Company compared logarithmic results from a competitor drug (vancomycin) to that of its Ibezapolstat drug, showing the differences in the effects on gut microbiome bacteria. Competitor drugs have been used for decades to treat CDI, but the reinfection rates are very high and greatly diminished gut microbiome bacteria. ACXP's Ibezapolstat study results have shown to combat reinfections effectively. Based on the data and other publications regarding the market size for newly discovered and effective treatment of CDI, ACXP believes Ibezapolstat could be a market worth over $1B. Decades-old antibacterial drugs are not working due to changes in the molecular composition of CDI. Thousands of people worldwide die annually, with many catching CDI in hospitals and nursing homes. Acurx Pharmaceuticals, Inc. believes its Ibezapolstat drug is the next generation for effectively treating CDI. Throughout 2024, Investors and others should expect more exciting news about Ibezapolstat and other positive corporate ongoings. The on-screen QR code is available during the show; download or visit Acurx Pharmaceuticals, Inc.. - https://www.acurxpharma.com/.
Blue Castle Ventures, Ltd.'s () ("Blue Castle") Chief Executive Officer / Founder David Rojas talks with New to The Street's TV Host Jane King about the Company. As a leading strategic developer of financial products and educational services, Blue Castle Ventures, LTD is gaining brand recognition as a unique financial platform assisting its clients in their investment objectives and creating new innovative product/service verticals. In 2024, the Company will update its technology framework to allow more customers to access product and service options. David says Blue Castle is establishing itself in the US market and working on necessary regulatory approvals. More financial courses are becoming available for its clients to help provide more financial educational platforms, assisting clients to meet their financial objectives. The Company expects to continue to grow its client base from its asset-backed financial products, financial educational training courses, mortgages, digital art marketing, and other services. Blue Castle sees forthcoming upside demand from its AI (Artificial Intelligence) platform in the care-for-elders and anti-aging technology. The Company looks at current market trends and determines if entering other business verticals can meet clients' demands and generate profits. Blue Castle Ventures, Ltd. does not trade cryptocurrencies nor carry out transactions or investments with cryptocurrencies. All the Company's operations are in US dollars. The Company's blockchain, , is a cryptography and security system. The on-screen QR code is available during the show; download or visit Blue Castle Ventures, Ltd. - https://bluecastleventures.ca/.
From the Nasdaq MarketSite Studio, Clifford Mapp, an independent technology expert and blockchain pioneer, talks about Dynex (CRYPTO: DNX) () with New to The Street's TV Host Jane King. Clifford explains Dynex's technology platform that can provide supercomputing services to everyone and every industry at a fraction of the cost. Dynex offers a decentralized supercomputer platform, disrupting the supercomputing hardware and software legacy industries. Using a neuromorphic blockchain-based algorithm on its DynexSolve Chip, Dynex creates quantum-level computation services ...